GlassScriptPhysician profile
Anand D Patel
NPI 1851654586
$9,365.99
in general payments reported to CMS, 2019-2025
28 companies · $81.48 in 2025
The $81.48 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $2,937 · 2021: $1,488 · 2022: $147 · 2023: $144 · 2024: $3,299 · 2025: $81.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,008 · Food and Beverage: $477 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,008.00 |
| Food and Beverage | $476.54 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $4,296.71 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $2,953.72 | 2019-2022 | |
| Genentech USA, INC. | $356.14 | 2019 | |
| Amgen INC. | $263.44 | 2021-2024 | Imdelltra (Amg 757), Lumakras |
| E.R. Squibb & Sons, L.L.C. | $231.98 | 2019-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $182.78 | 2019-2021 | |
| Celgene Corporation | $145.02 | 2019 | |
| Adc Therapeutics America, INC. | $144.18 | 2023 | |
| Janssen Biotech, INC. | $125.90 | 2024 | Akeega, Erleada |
| Daiichi Sankyo INC. | $125.00 | 2020 | |
| Incyte Corporation | $123.09 | 2019 | |
| Lilly USA, LLC | $79.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.34 | 2019 | |
| Aveo Pharmaceuticals, INC. | $40.00 | 2025 | |
| Genzyme Corporation | $33.81 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $30.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.03 | 2019 | |
| Geron Corporation | $19.76 | 2025 | Rytelo |
| Eisai INC. | $17.07 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $14.35 | 2019 | |
| Emd Serono, INC. | $12.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.62 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Exelixis INC. | $11.67 | 2019 | |
| Puma Biotechnology, INC. | $11.54 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.